Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Edicotinib |
| Synonyms | |
| Therapy Description |
Edicotinib (JNJ-40346527) is a small molecule inhibitor of CSF1R, which may inhibit growth of CSF1R-expressing tumor cells (PMID: 25628399). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Edicotinib | JNJ-40346527 | CSF1R Inhibitor 28 | Edicotinib (JNJ-40346527) is a small molecule inhibitor of CSF1R, which may inhibit growth of CSF1R-expressing tumor cells (PMID: 25628399). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03557970 | Phase II | Edicotinib | CSF1R Inhibitor JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia | Terminated | USA | 0 |
| NCT03177460 | Phase I | Daratumumab Edicotinib | Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer | Completed | USA | 0 |